RJFSA
HAE icon

Raymond James Financial Services Advisors’s Haemonetics HAE Stock Holding History

Raymond James Financial Services Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,696
Closed -$201K – 3225
2020
Q4 		$201K Buy
+1,696
New +$183K ﹤0.01% 2711
2018
Q4 		– Sell
-2,289
Closed -$262K – 2660
2018
Q3 		$262K Buy
+2,289
New +$237K ﹤0.01% 2358

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial Services Advisors's HAE Position: Q1 2021 in Review

Raymond James Financial Services Advisors sold out of Haemonetics (HAE) in Q1 2021, closing a stake of 1,696 shares — an estimated $201K sold.

Raymond James Financial Services Advisors first reported a position in HAE in Q3 2018 and held it in 2 quarters. The position peaked at $262K in Q3 2018. 296 funds tracked by Wall St. Rank hold HAE as of Q1 2021.

  • Raymond James Financial Services Advisors reported no remaining Haemonetics position as of Q1 2021 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 1,696 Haemonetics shares in Q1 2021, an estimated $201K.
  • Raymond James Financial Services Advisors first reported a position in Haemonetics in Q3 2018 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Haemonetics position peaked at $262K in Q3 2018.
  • 296 funds tracked by Wall St. Rank held Haemonetics as of Q1 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2021, filed 14 May 2021.